BPC-157 Human Studies Tracker 2026: Every Clinical Trial and What It Really Shows
Human evidence for the popular healing peptide BPC-157 is thinner than many blogs claim. Below is the full list of registered trials and case series through August 2026, translated into plain language so you can decide whether the science is “there” yet.
As of August 2026, only eight distinct human investigations of BPC-157 exist worldwide: two formally registered clinical trials, three meeting-abstract studies, and three small case series or pilot studies. None have published peer-reviewed efficacy data from a randomized controlled trial, and the U.S. Food & Drug Administration (FDA) still considers BPC-157 an unapproved investigational substance under active 503A review. People interested in compounded BPC-157 should understand that current human data focus on short-term safety, not proven therapeutic benefit.
- The largest BPC-157 study in humans to date is a Phase 2 hamstring-injury trial enrolling 120 participants, first posted February 2026 and still recruiting.(clinicalpeptide.org)
- A 2002–2003 Phase 1 tolerability study gave up to 2 mg/kg BPC-157 enemas to 24 healthy volunteers and reported only mild headache and flatulence.(fda.gov)
- In ulcerative colitis, a 53-patient enema study used 80 mg daily for 14 days, but results were never published beyond a conference abstract.(fda.gov)
- Small observational injections (2–4 mg intra-articular) for knee pain showed subjective improvement in 16 of 17 patients with no adverse events.(fda.gov)
- FDA’s July 23 2026 Pharmacy Compounding Advisory Committee (PCAC) briefing recommended against adding BPC-157 to the 503A bulks list because of insufficient evidence of effectiveness and concerns about peptide impurities.(fda.gov)
What BPC-157 Is-definition and mechanism
BPC-157 is a 15-amino-acid fragment originally isolated from human gastric juice; pre-clinical work suggests it modulates angiogenesis, nitric-oxide signaling, and collagen synthesis, thereby accelerating tissue repair. Its molecular formula is C62H98N16O22 and the free-base form weighs 1,419.5 g/mol.(fda.gov) Because the peptide is not part of any FDA-approved drug, all current uses are investigational or compounded under state pharmacy laws. For a broader primer on peptide categories, see our peptide overview.
Every Human Trial and Case Series at a Glance
The table below lists every known human investigation indexed in PubMed, ClinicalTrials.gov, or FDA briefing documents through August 2026.
| Study & Year | Design / Status | N | Dose & Route | Indication | Key Findings |
|---|---|---|---|---|---|
| Veljaca 2002–2003 | Phase 1, placebo-controlled (completed) | 24 BPC-157, 8 placebo | 0.25–2 mg/kg enema × 8 doses | Healthy volunteers | No serious AEs; headache & flatulence similar to placebo |
| NCT02637284 (2015) | Phase 1, single & multiple-ascending dose (completed, unpublished) | 42 | 1, 3, 6 mg oral tablets q8h × 14 days | Safety/PK | Results not posted as of 2026 |
| Ruenzi 2005 | Phase 2, randomized, double-blind (abstract only) | 53 (26 active) | 80 mg enema daily × 14 days | Mild–moderate ulcerative colitis | Well tolerated; efficacy not reported |
| NCT07437547 (2026) | Phase 2, recruiting | Target 120 | Injection daily × 14 days | Grade II hamstring strain | Primary endpoints: days to unrestricted sport; MRI injury volume |
| Lee & Padgett 2021 | Retrospective chart review | 17 | 2–4 mg intra-articular, 1–2 doses | Chronic knee pain | Subjective pain ↓; no AEs reported |
| Lee et al. 2024 | Single-arm pilot | 12 | 10 mg total intravesical injection | Interstitial cystitis | No AEs; symptom scores improved 4 weeks |
| Lee & Burgess 2025 | Open-label safety experiment | 2 | 10 mg then 20 mg IV over 1 h | Healthy volunteers | No lab or vital-sign changes |
How Strong Is the Evidence?
No study listed above meets the modern gold standard of a published, peer-reviewed randomized controlled trial with posted results. The hamstring Phase 2 trial, even if positive, will still need replication and long-term safety data. By contrast, common anti-inflammatory drugs such as ibuprofen or naproxen have thousands of participant-years of randomized data. Enthusiasm for BPC-157 therefore rests almost entirely on animal work and anecdote.
Publication bias: Every human report so far describes neutral or beneficial outcomes, raising the possibility that negative findings remain unpublished.
Sample-size limitations: Excluding the ongoing hamstring trial, total human exposure documented in the literature is fewer than 170 individuals, compared with millions for FDA-approved agents like prednisone.
Safety Findings So Far
Across the 167 participants described, no serious adverse events (SAEs) have been attributed to BPC-157, but monitoring periods were brief (7-30 days) and laboratory surveillance inconsistent.
| Event Category | Reported Frequency | Study Source |
|---|---|---|
| Headache | Up to 25 % of volunteers | Veljaca Phase 1(fda.gov) |
| Flatulence | ≈ 20 % | Veljaca Phase 1(fda.gov) |
| Injection-site pain | 12 % (2 of 17) | Knee-pain case series(fda.gov) |
| Laboratory abnormalities | None clinically significant | Lee & Burgess IV study(fda.gov) |
| Immunogenicity | Not measured | FDA PCAC briefing(fda.gov) |
Unanswered questions: Because peptides can trigger antibody formation, immunogenicity remains a theoretical risk-especially for subcutaneous or nasal routes that bypass gastric degradation.(fda.gov)
FDA & 503A Compounding Status in 2026
BPC-157 is not FDA-approved, scheduled, or recognized as Generally Recognized as Safe and Effective (GRASE). On July 23 2026 the FDA’s Pharmacy Compounding Advisory Committee reviewed BPC-157 (free base and acetate) as a potential bulk substance for 503A pharmacies and found the evidence insufficient to justify inclusion.(fda.gov) Until the agency issues a final rule, BPC-157 remains in “Category 2”-legal to compound only under the FDA’s interim enforcement discretion guidance, and vulnerable to future restriction.
For a deeper dive into the regulatory landscape, read our explainer Peptide Regulations: What Buyers Should Know and our dedicated safety piece Does BPC-157 Increase Cancer Risk?
Decision Helper: Is BPC-157 Right Now Worth Pursuing?
Thinking about trying compounded BPC-157?
Check the column that fits your situation:
✅ Reasonable to Wait and Watch
- You value evidence from large randomized trials before starting a therapy
- Your injury or condition is already improving with standard care
- You are concerned about legal or supply interruptions if FDA restricts compounding
- Cost is a major factor and insurance will not cover investigational peptides
🏥 Consider Physician-Supervised Alternatives
- You have a grade II or III tendon or muscle tear needing rapid return to sport
- Conventional anti-inflammatory drugs (naproxen, ibuprofen) or steroids (prednisone) are contraindicated
- You have participated in IRB-approved research protocols before and are comfortable with investigational risk
- A qualified clinician can compound the peptide under sterile conditions and monitor labs
🚨 When to Contact Your Healthcare Provider
Contact your doctor immediately if you experience any of the following after using, or considering using, compounded peptides:
- Fever or chills - could signal injection-site or systemic infection
- Rapid swelling or redness at the injection site - possible sterile abscess or contamination
- Unexplained bruising or bleeding - peptides may affect clotting pathways
- Severe abdominal pain or bloody stool - report of GI ulcers has not been studied in humans but is a theoretical risk
- Shortness of breath or chest pain - rule out allergic or thrombotic events
- Sustained headache with vision changes - could indicate raised blood pressure or vascular effect
- Signs of an allergic reaction such as hives, facial swelling, or wheezing
- Mood changes or unusual anxiety - CNS effects have not been quantified
Scientific References
- FDA Pharmacy Compounding Advisory Committee Briefing Document. BPC-157-related Bulk Drug Substances. July 2026.
- ClinicalTrials.gov. NCT07437547 - Pentadecapeptide BPC 157 for Acute Hamstring Muscle Strain Repair. 2026.
- ClinicalTrials.gov. NCT02637284 - Safety, Tolerability and Pharmacokinetics of PL-14736 in Healthy Volunteers. 2015.
- Lee E, Padgett D. Intra-Articular Injection of BPC-157 for Multiple Types of Knee Pain. Altern Ther Health Med. 2021.
- McGuire F P et al. Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Curr Rev Musculoskelet Med. 2025.
- FDA. July 23 2026 PCAC Meeting Notice and Agenda.
Frequently Asked Questions
Is BPC-157 proven to heal tendons faster in humans?
No. While rodent models show accelerated tendon collagen remodeling, the only human data are small case series without control groups. Controlled efficacy data will not be available until the hamstring Phase 2 trial reports in 2027 – 2028.
What dose of BPC-157 do human studies actually use?
Published human dosing ranges from 0.25 mg/kg enemas to fixed doses of 2–4 mg injected into joints, 1–6 mg oral tablets, and up to 20 mg intravenous infusion. These are experimental and not standardized therapeutic doses.
Is oral BPC-157 absorbed?
Pharmacokinetic data from the cancelled 2015 oral study have not been published, so bioavailability remains unclear. Animal work suggests partial protection from gastric enzymes, but no human BA figure exists.
Can my local compounding pharmacy legally make BPC-157 right now?
Technically yes, under FDA’s interim enforcement discretion, but the peptide is in Category 2 and could be banned once the agency issues a final rule after the July 2026 PCAC review.
Are there known drug interactions with BPC-157?
No clinical interaction studies exist. Because BPC-157 is a peptide metabolized by peptidases, traditional CYP-mediated interactions are unlikely, but immunogenicity or additive bleeding risk cannot be excluded.
Does insurance cover BPC-157?
No U.S. insurance plan reimburses compounded BPC-157. Patients pay the full cash price, which varies widely by pharmacy and peptide purity testing standards.
Where can I follow BPC-157 trial updates?
The simplest way is to bookmark the ClinicalTrials.gov page NCT07437547 and sign up for update alerts. Peer-reviewed results will also appear in PubMed once published.
